(redirected from C-myc)
Also found in: Dictionary.


Any of several genes encoding DNA-binding proteins that can promote the development of various cancers when present at high concentrations.


An oncogene on chromosome 8q24 of cellular (c-myc) or viral (v-myc) origin, which was first identified in the genome of a group of acutely transforming retroviruses capable of inducing avian neoplasia, possibly linked to RNA processing.

c-myc is present in normal tissues; the protein product is required for progression through the cell cycle. Myc-null cell lines show profound growth defect, with lengthening of G1 and G2 phases of the cell cycle. There is a marked reduction in cyclin D1-CDK4 and D1-CDK6 complexes during entry to S phase, with lesser reductions in cyclin E2-CDK2 and cyclin A-CDK2. Myc induces expression of cyclins D1 and D2.

Oncogenic expression of c-myc involves mutations on exon 2, which occur in more than 50% of Burkitt's lymphomas. The typical translocation in Burkitt’s lymphoma is t(8;14)(q24;q23), juxtaposing the c-myc and the immunoglobulin heavy-chain genes. Variant translocations are to 2p11 or 22q11, juxtaposing kappa or lambda light-chain genes respectively. FISH performed with dual probes can demonstrate the IgH/c-myc translocation. Tricolour with a probe against the centromere of chromosome 8 will control c-myc amplification or loss of the derivative chromosome 8; dual colour break-apart probes will show splitting of the gene.
References in periodicals archive ?
Finalmente, se presentan modificaciones postraduccionales de la proteina c-Myc, como glicosilacion y fosforilacion, que alteran su vida media; por ejemplo, la fosforilacion del dominio de transactivacion transcripcional de c-Myc constituye un sustrato para la accion de factores de crecimiento regulados por las proteinas MAP quinasas (por la sigla en ingles de mitogen-activated protein kinases), asi como para proteinas quinasas dependientes del ciclo celular.
Using the chemotherapy drug, cisplatin (which is commonly used as a first-line therapy for various cancers) to design a set of experiments, the research team found that the c-MYC oncoprotein increases cisplatin resistance by decreasing production of a c-MYC inhibitor called BIN1.
Novus Biologicals provides THAP11-related products, such as c-Myc antibodies, OCT4 antibodies, and Nanog antibodies, as well as other THAP-11 antibodies.
Keywords: C-myc gene, Gene expression, hTERT, Lentinan, Telomerase
The animal studies just completed have shown conclusively that the c-myc inhibitor (AVI-5126) we have been exploring produces a therapeutic effect at the dosages used.
Scientists have been aware of a link between cancer and c-Myc for many years, but until now, the exact nature of that link has not been fully understood.
c-myc gene amplification that leads to overexpression has been shown to play a major role in cancer development, especially in breast cancer (1).
Figure 2A showed the age-related change of DNA methylation of the c-myc gene in mouse liver.
The targets of ROS also include growth factors, inflammatory factors, and cell cycle regulators, including c-Myc, NF-[kappa]B, NF-E2-related factor 2 (Nrf2), hypoxia-inducible factor 1 (HIF-1[alpha]), and Protein Kinase C (PKC), and some of these factors are closely associated with multidrug resistance (MDR) in tumor [7].
Blocking transcription of the c-Myc gene (in other words, reducing production of the c-Myc protein) prevented these effects.